Trial in Progress: A Phase 3, Randomized, Double-Blind Study of Midostaurin in Combination with Chemotherapy and as Single-Agent Maintenance Therapy in Newly Diagnosed Patients with FLT3 Mutation-Negative Acute Myeloid Leukemia

被引：2
|
作者：
Doehner, Hartmut [1 ]
Sierra, Jorge [2 ]
Stone, Richard [3 ]
Hoenekopp, Albert [4 ]
Berkowitz, Noah [5 ]
Sachs, Carolin [4 ]
Bengoudifa, Bourras-Rezki [4 ]
Ossenkoppele, Gert [6 ]
机构：
[1] Univ Ulm, Dept Internal Med 3, Ulm, Germany
[2] Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Novartis Pharma AG, Basel, Switzerland
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷
关键词：
FLT3; wild type; leukemia; midostaurin; chemotherapy;
D O I：
10.1016/j.clml.2018.07.060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-240
引用
收藏
页码：S206 / S207
页数：2
相关论文
共 13 条
  • [1] Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive
    Garcia, J. S.
    Percival, M. E.
    DRUGS OF TODAY, 2017, 53 (10) : 531 - 543
  • [2] Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
    Stone, R. M.
    Fischer, T.
    Paquette, R.
    Schiller, G.
    Schiffer, C. A.
    Ehninger, G.
    Cortes, J.
    Kantarjian, H. M.
    DeAngelo, D. J.
    Huntsman-Labed, A.
    Dutreix, C.
    del Corral, A.
    Giles, F.
    LEUKEMIA, 2012, 26 (09) : 2061 - 2068
  • [3] Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
    R M Stone
    T Fischer
    R Paquette
    G Schiller
    C A Schiffer
    G Ehninger
    J Cortes
    H M Kantarjian
    D J DeAngelo
    A Huntsman-Labed
    C Dutreix
    A del Corral
    F Giles
    Leukemia, 2012, 26 : 2061 - 2068
  • [4] Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia
    Kim, Miryoung
    Williams, Sherry
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (04) : 364 - 369
  • [5] Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia
    Luskin, Marlise R.
    DeAngelo, Daniel J.
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1033 - 1045
  • [6] Evaluating the clinical significance of FLT3 mutation status in Syrian newly diagnosed acute myeloid leukemia patients with normal karyotype
    Moualla, Yahia
    Moassass, Faten
    AL-Halabi, Bassel
    Al-achkar, Walid
    Georgeos, Michael
    Yazigi, Haissam
    Khamis, Atieh
    HELIYON, 2022, 8 (11)
  • [7] Effects of Dietary Honey and Ardeh Combination on Chemotherapy-Induced Gastrointestinal and Infectious Complications in Patients with Acute Myeloid Leukemia: A Double-Blind Randomized Clinical Trial
    Ebrahimi, Mahmoud
    Allahyari, Abolghasem
    Ebrahimi, Mohsen
    Mostafavi-Toroghi, Hesam
    Hosseini, Golkoo
    Karimi, Mohammad
    Rezaiean, Amin
    Kazemi, Mohammad Reza
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 15 (02): : 661 - 668
  • [8] Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
    Fischer, Thomas
    Stone, Richard M.
    DeAngelo, Daniel J.
    Galinsky, Ilene
    Estey, Elihu
    Lanza, Carlo
    Fox, Edward
    Ehninger, Gerhard
    Feldman, Eric J.
    Schiller, Gary J.
    Klimek, Virginia M.
    Nimer, Stephen D.
    Gilliland, D. Gary
    Dutreix, Catherine
    Huntsman-Labed, Alice
    Virkus, Jodi
    Giles, Francis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : 4339 - 4345
  • [9] A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
    Harousseau, Jean-Luc
    Martinelli, Giovanni
    Jedrzejczak, Wieslaw W.
    Brandwein, Joseph M.
    Bordessoule, Dominique
    Masszi, Tamas
    Ossenkoppele, Gert J.
    Alexeeva, Julia A.
    Beutel, Gernot
    Maertens, Johan
    Vidriales, Maria-Belen
    Dombret, Herve
    Thomas, Xavier
    Burnett, Alan K.
    Robak, Tadeusz
    Khuageva, Nuriet K.
    Golenkov, Anatoly K.
    Tothova, Elena
    Mollgard, Lars
    Park, Youn C.
    Bessems, Annick
    De Porre, Peter
    Howes, Angela J.
    BLOOD, 2009, 114 (06) : 1166 - 1173
  • [10] Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial
    Martinelli, Giovanni
    Santoro, Armando
    Gambacorti-Passerini, Carlo
    Polo, Susana Vives
    Solomon, Scott R.
    Mukherjee, Sudipto
    Lech-Maranda, Ewa
    Levy, Moshe Yair
    Wierzbowska, Agnieszka
    Calbacho-Robles, Maria
    Marconi, Giovanni
    Giannini, Maria Benedetta
    Cano, Isabel
    Minana, Laura Torres
    Acuna-Cruz, Evelyn
    Angelosanto, Noemi
    Mughal, Tariq I.
    Galleu, Antonio
    Blotta, Simona
    Ravandi, Farhad
    Montesinos, Pau
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S243 - S244
12